FDA Advisory Committee Rejects Deramiocel for DMD Cardiomyopathy — Capricor Therapeutics, Inc.

Event summary

The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support the effectiveness of Deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy (DMD) patients.
The vote was non-binding but addressed a narrower indication than Capricor had proposed.
Committee feedback on upper limb function was directionally supportive of clinical evidence from the Phase 3 HOPE-3 trial.
Capricor remains committed to Deramiocel and is working with the FDA toward potential approval ahead of the August 22, 2026 PDUFA target action date.

The big picture

The FDA Advisory Committee's vote highlights the challenges of bringing cell-based therapies to market for rare diseases like DMD. Capricor's Deramiocel faces a critical juncture as it navigates regulatory hurdles, with potential implications for other cell and exosome-based therapeutics in development.

What we're watching

Regulatory Pathway: Whether Capricor can secure FDA approval for Deramiocel despite the negative advisory committee vote.
Clinical Evidence: The impact of the Committee's supportive feedback on upper limb function on future clinical strategies.
Market Dynamics: How the unmet need in DMD cardiomyopathy treatment could influence regulatory decisions and commercial prospects.